Aerie Pharmaceuticals reports positive Roclatan(TM) phase 3 topline efficacy results
Aerie Pharma reported the successful primary efficacy results of the Company's 90-day Phase 3 "Mercury 2" registration trial for its fixed-dose combination product candidate, Roclatan™. The results of Mercury 2 were consistent with the successful 90-day efficacy results from the Mercury 1 trial. May 24, 2017